A Multicenter, Open-label, Randomized Controlled Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer With Disease Progression After Previous Endocrine Therapy
This study is a multicenter, open-label, randomized controlled Phase 3 clinical trial. It is planned to enroll 240 female patients with locally advanced or metastatic breast cancer followed by disease progression after previous endocrine therapy.
• Women aged 18 to 75 years old (including both values).
• ECOG Physical Strength Status (PS) : 0 to 1 point.
• Patients with locally advanced or metastatic breast cancer confirmed by histology.
• Patients previously received 1-2 lines of endocrine therapy.
• Expected survival \> 6 months.
• The functional level of the organs must meet the requirements.
• Subjects that voluntarily participate in this clinical trial, be willing and able to abide by the procedures related to clinical visits and research, understand the research procedures and have signed the informed consent.